Veru Inc (VERU) - Total Liabilities

Latest as of September 2025: $10.44 Million USD

Based on the latest financial reports, Veru Inc (VERU) has total liabilities worth $10.44 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Veru Inc - Total Liabilities Trend (1990–2025)

This chart illustrates how Veru Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Veru Inc to evaluate short-term liquidity relative to the company's equity base.

Veru Inc Competitors by Total Liabilities

The table below lists competitors of Veru Inc ranked by their total liabilities.

Company Country Total Liabilities
Cyclone Metals Ltd
AU:CLE
Australia AU$1.18 Million
Li Kang Biomedical Co Ltd
TWO:6242
Taiwan NT$221.82 Million
Brunswick Exploration Inc
V:BRW
Canada CA$965.97K
Piolink Inc
KQ:170790
Korea ₩15.06 Billion
Theradiag SA
PA:ALTHE
France €14.09 Million
AMICCOM Electronics
TWO:5272
Taiwan NT$147.54 Million
Sangji Caelum Inc
KQ:042940
Korea ₩118.95 Billion
WIZIT Co. Ltd
KQ:036090
Korea ₩273.85 Billion

Liability Composition Analysis (1990–2025)

This chart breaks down Veru Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Veru Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.16 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.28 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Veru Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Veru Inc (1990–2025)

The table below shows the annual total liabilities of Veru Inc from 1990 to 2025.

Year Total Liabilities Change
2025-09-30 $11.50 Million -59.07%
2024-09-30 $28.10 Million -7.39%
2023-09-30 $30.34 Million -42.27%
2022-09-30 $52.56 Million +103.31%
2021-09-30 $25.85 Million +20.62%
2020-09-30 $21.43 Million +0.64%
2019-09-30 $21.30 Million +12.25%
2018-09-30 $18.97 Million +176.82%
2017-09-30 $6.85 Million +46.11%
2016-09-30 $4.69 Million +8.10%
2015-09-30 $4.34 Million +20.26%
2014-09-30 $3.61 Million -4.23%
2013-09-30 $3.77 Million -39.52%
2012-09-30 $6.23 Million +131.52%
2011-09-30 $2.69 Million +20.31%
2010-09-30 $2.24 Million -59.97%
2009-09-30 $5.59 Million +35.53%
2008-09-30 $4.12 Million +10.02%
2007-09-30 $3.75 Million +40.12%
2006-09-30 $2.67 Million +12.84%
2005-09-30 $2.37 Million -11.26%
2004-09-30 $2.67 Million -41.22%
2003-09-30 $4.54 Million -7.91%
2002-09-30 $4.93 Million +15.29%
2001-09-30 $4.28 Million -11.12%
2000-09-30 $4.81 Million +0.62%
1999-09-30 $4.78 Million +3.46%
1998-09-30 $4.62 Million -3.35%
1997-09-30 $4.78 Million -22.67%
1996-09-30 $6.19 Million -0.20%
1995-09-30 $6.20 Million +5.08%
1994-09-30 $5.90 Million +1.72%
1993-09-30 $5.80 Million +26.09%
1992-09-30 $4.60 Million +31.43%
1991-09-30 $3.50 Million +16.67%
1990-09-30 $3.00 Million --

About Veru Inc

NASDAQ:VERU USA Biotechnology
Market Cap
$47.99 Million
Market Cap Rank
#23106 Global
#4982 in USA
Share Price
$2.99
Change (1 day)
-4.47%
52-Week Range
$0.37 - $4.43
All Time High
$23.78
About

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosa… Read more